Astellas PharmaALPMF 73 3-Year ROIIC % is 17.71 as of Mar. 2026, which is 223% above its 10-year median of 5.49. GuruFocus rates ALPMF with a GF Score™ of 73/100 and a GF Value™ of $14.60 (Fairly Valued). The stock has 4 warning signs investors should review. Among 941 Drug Manufacturers companies, Astellas Pharma ranks better than 68.33% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Astellas Pharma's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 17.71%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Astellas Pharma's 3-Year ROIIC % or its related term are showing as below:
ALPMF's 3-Year ROIIC % is ranked better than 68.33% of 941
companies
in the Drug Manufacturers industry
Industry Median: 3.74
vs ALPMF: 17.71
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Astellas Pharma 3-Year ROIIC % Related Terms
Astellas Pharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Astellas Pharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALPMF vs LLY, JNJ, ABBV: 3-Year ROIIC % Comparison
For the Drug Manufacturers - General subindustry, Astellas Pharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Astellas Pharma (ALPMF) has a 3-Year ROIIC % of 17.71 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Astellas Pharma and its competitors. This is 223% above median its historical median of 5.49. According to the industry distribution chart, Astellas Pharma ranks #298 out of 941 companies in the Drug Manufacturers industry, placing it in the top 31.7%.
Is Astellas Pharma's 3-Year ROIIC % too high?
Astellas Pharma's current 3-Year ROIIC % of 17.71 is 223% above median its 10-year median of 5.49. The Drug Manufacturers industry median 3-Year ROIIC % is 3.74. Astellas Pharma's value of 17.71 is 373.5% above this industry median. Based on the distribution chart, Astellas Pharma ranks #298 out of 941 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Astellas Pharma has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's 3-Year ROIIC % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #298 out of 941 companies for 3-Year ROIIC %. This puts Astellas Pharma in the upper half of its industry. The industry median 3-Year ROIIC % is 3.74. Astellas Pharma's value of 17.71 is 373.5% above this benchmark. While the company's 10-year median is 5.49 vs. the industry median of 3.74, Astellas Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.74, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current 3-Year ROIIC % of 17.71 is 373.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Astellas Pharma and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current 3-Year ROIIC % is 17.71, which is 223% above median its own 10-year median of 5.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.60, compared to a current price of $14.15 — trading 3.1% below its estimated fair value. The current 3-Year ROIIC % is 17.71, which is 223% above median its 10-year median of 5.49 and 373.5% above the Drug Manufacturers industry median of 3.74. Astellas Pharma's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current 3-Year ROIIC % is 17.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued.
The current stock price of $14.15 is trading 3.1% below its estimated GF Value™ of $14.60.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for ALPMF:
3-Year ROIIC %: 17.71 (223% above median its 10-year median of 5.49)
GF Value™: $14.60 vs. price of $14.15 (3.1% below fair value)
Industry Position: 373.5% above the Drug Manufacturers median (#298 of 941)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
73GF Score
Get the complete analysis for ALPMF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
